MMV achievements in 2022 26 June 2023 Throughout 2022, MMV helped treat and protect millions of people against malaria while making significant progress in multiple key areas. See the infographic below for more details.
Annual Report 2022 26 June 2023 Read an in-depth overview of MMV's activities and our financial statements for 2022.
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial 12 June 2023 Lancet Infect Dis
Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria 6 June 2023
Rectal artesunate for severe malaria, implementation research, Zambia 31 May 2023 Bull World Health Organ
Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum 26 May 2023 Nat Commun
Breaking barriers: The power of inclusive R&D to accelerate malaria elimination 24 May 2023 MMV's Chief of Corporate Strategy and Affairs Andrea Lucard spoke at "Breaking barriers: The power of inclusive R&D to accelerate malaria elimination," hosted by Devex in partnership with MMV.
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study 22 May 2023 Lancet Infect Dis
Integration and application of new approach methodologies in assessing the developmental hazards: Case study with an antimalarial drug 22 May 2023 Birth Defects Res
Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X 20 May 2023
Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline 9 May 2023 American Society for Microbiology
Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model 3 May 2023 Antimicrobial Agents and Chemotherapy
Partnership for Vivax Elimination (PAVE) Peru vlog 27 April 2023 A video blog from the MMV Peru team following the launch of the PAVE Peru feasibility study in March 2023.
